A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs TD 1473 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms DIONE
- Sponsors Theravance Biopharma
- 25 Nov 2019 Planned End Date changed from 1 Sep 2020 to 1 Dec 2021.
- 25 Nov 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Nov 2020.
- 31 Jul 2019 According to a Theravance Biopharma media release, data from this study planned late-2020.